(Q33545307)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10093591%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

review article

1 reference

title

Neuroprotective therapies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10093591%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10093591%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

author name string

D K Simon

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10093591%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

publication date

1 March 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10093591%20AND%20SRC:MED&resulttype=core&format=json

Medical Clinics of North America

12 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10093591%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

volume

83

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10093591%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10093591%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

page(s)

509-23, viii

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10093591%20AND%20SRC:MED&resulttype=core&format=json

A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease.

12 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Alternative excitotoxic hypotheses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Genetic aspects of Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Aging, energy, and oxidative stress in neurodegenerative diseases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Gene therapeutic strategies for neuroprotection: implications for Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Detection of preclinical Parkinson's disease with PET.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Aminooxyacetic acid striatal lesions attenuated by 1,3-butanediol and coenzyme Q10.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Aetiology of Parkinson's disease

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

inferred from DOI database lookup

7 January 2021

based on heuristic

Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Association of a polymorphism in intron 13 of the monoamine oxidase B gene with Parkinson disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Expression of N-methyl-D-aspartate receptor subunit mRNA in the human brain: mesencephalic dopaminergic neurons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

The diversity of coenzyme Q function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Antioxidants and atherosclerotic heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Targets for gene therapy of Parkinson's disease: growth factors, signal transduction, and promoters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Cortical glucose metabolism in Parkinson's disease without dementia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Ubiquinone protects cultured neurons against spontaneous and excitotoxin-induced degeneration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Inhibition of monoamine oxidase B in the brains of smokers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Pharmacology of selegiline

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Cloned glutamate receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Parkinsons disease and its chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Bright and dark sides of nitric oxide in ischemic brain injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Mitochondrial encephalomyopathy (MELAS): pathological study and successful therapy with coenzyme Q10 and idebenone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Point mutations of mitochondrial genome in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Oxidative stress and the pathogenesis of Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

The antioxidant vitamins and cardiovascular disease. A critical review of epidemiologic and clinical trial data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Issues in the early diagnosis of Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

The etiology of Parkinson's disease with emphasis on the MPTP story

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Clinical observations on the rate of progression of idiopathic parkinsonism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Excitatory amino acids as a final common pathway for neurologic disorders.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Remission of Leber's hereditary optic neuropathy with idebenone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

beta-Carbolinium cations, endogenous MPP+ analogs, in the lumbar cerebrospinal fluid of patients with Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Bcl-2 gene family in the nervous system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Idebenone attenuates neuronal degeneration induced by intrastriatal injection of excitotoxins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Inhibition of mitochondrial alpha-ketoglutarate dehydrogenase by 1-methyl-4-phenylpyridinium ion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

The excitatory amino acid receptors: their classes, pharmacology, and distinct properties in the function of the central nervous system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Parkinson's disease is not a long-latency illness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Clinical experience with excitatory amino acid antagonist drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Molecular diversity of glutamate receptors and implications for brain function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Caspases: killer proteases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorders?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

A protective effect of coenzyme Q10 on ischemia and reperfusion of the isolated perfused rat heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

The effect of deprenyl and levodopa on the progression of Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Alpha-tocopherol in the ventricular cerebrospinal fluid of Parkinson's disease patients: dose-response study and correlations with plasma levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Effect of deprenyl on the progression of disability in early Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Parkinson Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

MELAS syndrome with mitochondrial tRNA(Leu)(UUR) mutation: correlation of clinical state, nerve conduction, and muscle 31P magnetic resonance spectroscopy during treatment with nicotinamide and riboflavin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Evaluation of four candidate genes encoding proteins of the dopamine pathway in familial and sporadic Parkinson's disease: evidence for association of a DRD2 allele.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Time course of nigrostriatal degeneration in parkinson's disease. A detailed study of influential factors in human brain amine analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

The identification of presymptomatic parkinsonism: clinical and [18F]dopa positron emission tomography studies in an Irish kindred

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Oxidative stress in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Mitochondrial dysfunction in movement disorders.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Coenzyme Q10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Possible environmental, occupational, and other etiologic factors for Parkinson's disease: a case-control study in Germany.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Mitochondrial DNA variants observed in Alzheimer disease and Parkinson disease patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Neuroprotective clinical strategies for Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Biochemical events in the development of parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Blockade of 1-methyl-4-phenylpyridinium ion (MPP+) nigral toxicity in the rat by prior decortication or MK-801 treatment: a stereological estimate of neuronal loss

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Inhibition of lipid peroxidation by a novel compound (CV-2619) in brain mitochondria and mode of action of the inhibition.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Origin and functional consequences of the complex I defect in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegeneration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

The effect of deprenyl (selegiline) on the natural history of Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Apoptosis in the pathogenesis and treatment of disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Amantadine treatment is an independent predictor of improved survival in Parkinson's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Mitochondrial DNA in aging and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Electrophysiologic analysis of early Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Mechanism of activation of pyruvate dehydrogenase by dichloroacetate and other halogenated carboxylic acids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

Nitric oxide activation of poly(ADP-ribose) synthetase in neurotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970117-6

10.1016/S0025-7125(05)70117-6

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10093591%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

1 reference